Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This Phase II study was designed as a multicenter, randomized, double-blind,
placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and
tolerabilityGN-037 versus clobetasol 17-propionate and placebo in patients diagnosed with
mild to moderate plaque psoriasis at least 6 months ago